Feasibility of cardiopulmonary exercise testing in interstitial lung disease: the PETFIB study.
exercise
interstitial fibrosis
Journal
BMJ open respiratory research
ISSN: 2052-4439
Titre abrégé: BMJ Open Respir Res
Pays: England
ID NLM: 101638061
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
02
10
2020
revised:
02
03
2021
accepted:
13
03
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
29
10
2021
Statut:
ppublish
Résumé
Cardiopulmonary exercise testing (CPET) provides a series of biomarkers, such as peak oxygen uptake, which could assess the development of disease status in interstitial lung disease (ILD). However, despite use in research and clinical settings, the feasibility of CPET in this patient group has yet to be established. Twenty-six patients with ILD (19 male) were recruited to this study. Following screening for contraindications to maximal exercise, participants underwent an incremental CPET to volitional exhaustion. Feasibility of CPET was assessed by the implementation, practicality, acceptability and demand, thus providing clinical-driven and patient-driven information on this testing procedure. Of the 26 recruited participants, 24 successfully completed at least one CPET, with 67/78 prospective tests being completed. Contraindications included hypertension, low resting oxygen saturation and recent pulmonary embolism. Of the CPETs undertaken, 63% successfully reached volitional exhaustion, with 31% being terminated early by clinicians due to excessive desaturation. Quantitative and qualitative feedback from participants revealed a positive experience of CPET and desire for it to be included as a future monitoring tool. CPET is feasible in patients with ILD. Identification of common clinical contraindications, and understanding of patient perspectives will allow for effective design of future studies utilising CPET as a monitoring procedure.
Identifiants
pubmed: 33926958
pii: 8/1/e000793
doi: 10.1136/bmjresp-2020-000793
pmc: PMC8094359
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: MG has received support to attend conferences and professional fees from Roche and Boehringer-Ingelheim.
Références
Eur Respir J. 2019 May 2;53(5):
pubmed: 30846470
Ann Am Thorac Soc. 2017 Jul;14(Supplement_1):S140-S148
pubmed: 28590162
BMC Pulm Med. 2015 Dec 04;15:155
pubmed: 26637194
Am J Prev Med. 2009 May;36(5):452-7
pubmed: 19362699
J Cardiopulm Rehabil Prev. 2019 May;39(3):193-198
pubmed: 31022002
Curr Respir Med Rev. 2015;11(2):163-174
pubmed: 27019654
Intern Med J. 2011 May;41(5):416-22
pubmed: 20059599
Physiother Theory Pract. 2019 Oct 18;:1-9
pubmed: 31625781
Pulm Med. 2013;2013:514817
pubmed: 24288606
Proc Am Thorac Soc. 2006 Jun;3(4):315-21
pubmed: 16738195
Thorax. 1993 Sep;48(9):894-8
pubmed: 8236071
PLoS One. 2018 May 23;13(5):e0197660
pubmed: 29791487
Sarcoidosis Vasc Diffuse Lung Dis. 2020;37(2):192-202
pubmed: 33093783
Eur Respir Rev. 2017 Feb 21;26(143):
pubmed: 28223398
Am J Respir Crit Care Med. 2009 Mar 1;179(5):402-7
pubmed: 19074597
Respirology. 2014 Feb;19(2):269-275
pubmed: 24251797
Lung. 2019 Dec;197(6):721-726
pubmed: 31676976
Ann Intern Med. 2012 May 15;156(10):684-91
pubmed: 22586007
Am J Respir Crit Care Med. 2003 Jan 15;167(2):211-77
pubmed: 12524257
Ther Adv Respir Dis. 2017 Feb;11(2):115-128
pubmed: 28150539
Am J Respir Crit Care Med. 2003 Sep 1;168(5):538-42
pubmed: 12773325
Am Rev Respir Dis. 1985 May;131(5):700-8
pubmed: 3923878
Biomed Res Int. 2015;2015:123876
pubmed: 26640781
Am J Respir Crit Care Med. 2005 Mar 15;171(6):639-44
pubmed: 15640368
Psychol Bull. 1992 Jul;112(1):155-9
pubmed: 19565683
Thorax. 2013 Sep;68 Suppl 2:ii1-30
pubmed: 23880483